Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

Oppenheimer reiterated an Outperform rating on Veru Inc. (NASDAQ:VERU), which has seen remarkable momentum with a 200% return over the past year and a 96% gain year-to-date. Anticipation is building ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

InvestingPro data shows the stock has demonstrated strong resilience, often moving independently of broader market trends. The focus is on the potential of enobosarm, Veru's investigational drug ...